BMRN — BioMarin Pharmaceutical Inc.

Summary of BioMarin Pharmaceutical Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $3.22 billion for the full year 2025, a 13% increase year-over-year.
• Q4 Revenues: $875 million, representing a 17% year-over-year growth.
• Voxzogo Revenue: $927 million for the full year, a 26% increase; Q4 growth of 31%.
• Enzyme Therapies Revenue: Increased by 9% year-over-year, with Palynziq growing 22% in Q4.
• Non-GAAP Diluted EPS: $3.15 for the full year, with underlying business EPS growth of approximately 34%.
• Operating Cash Flow: $828 million, a 45% increase compared to 2024.

2. Strategic Updates and Business Highlights

• Acquisitions: BioMarin announced the acquisition of Inozyme and Amicus, enhancing its enzyme therapies portfolio and expanding treatment options for rare diseases.
• Pipeline Expansion: Anticipated pivotal data for BMN 401 (ENPP1 deficiency) and BMN 333 (long-acting CNP therapy for achondroplasia) expected in 2026.
• Voxzogo: Plans for a potential indication expansion to treat hypochondroplasia, with pivotal results expected soon.
• Operational Excellence: Continued focus on improving operational efficiency and cash flow generation.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenues between $3.325 billion to $3.425 billion, excluding contributions from Amicus products.
• Voxzogo Revenue Guidance: Projected between $975 million to $1.025 billion; enzyme therapies expected to generate $2.225 billion to $2.275 billion.
• Non-GAAP Diluted EPS Guidance: Anticipated in the range of $4.95 to $5.15 for 2026.
• Operating Margin: Expected to remain around 40%, though slightly diluted by the Amicus acquisition.

4. Bad News, Challenges, or Points of Concern

• Withdrawal of Roctavian: BioMarin withdrew Roctavian from the market, resulting in a $240 million charge, impacting GAAP earnings.
• Market Access Negotiations: Anticipated routine market access renegotiations could lead to lower revenue growth in 2026.
• Competition: Concerns regarding potential competition for Voxzogo, particularly from new entrants in the achondroplasia market, which may affect new patient starts and market dynamics.
• Q1 Revenue Expectations: Q1 2026 is expected to be the lowest revenue quarter, influenced by large order timing in Q4 2025.

5. Notable Q&A Insights

• Market Dynamics: Discussion on how the achondroplasia market may evolve with new oral therapies; BioMarin emphasized the importance of long-term safety and efficacy data for Voxzogo.
• BMN 333 Confidence: The company expressed confidence in BMN 333's potential to outperform existing therapies based on preclinical data and study design.
• Hypochondroplasia Launch: Expected to see immediate revenue impact post-approval, with a focus on improving diagnosis rates for this underdiagnosed condition.
• Integration of Amicus: Plans to integrate Amicus products into BioMarin’s existing enzyme therapy business unit, leveraging existing commercial infrastructure for efficiency.

Overall, BioMarin demonstrated strong financial performance in 2025, with promising growth prospects for 2026, despite facing challenges from market competition and the withdrawal of Roctavian. The company remains focused on expanding its product portfolio and improving patient access to its therapies.